Residual cardiovascular disease risk in heart failure patients. What is the real role of lipid-lowering therapy?

Maddox TM, Januzzi JL Jr, Allen LA, et al. 2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2024; 83: 1444-88.

Google Scholar

McDonagh TA, Metra M, Adamo M, et al.; ESC Scientific Document Group. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2023; 44: 3627-39.

Google Scholar

Hilfiker-Kleiner D, Landmesser U, Drexler H. Molecular mechanisms in heart failure. Focusing on cardiac hypertrophy, inflammation, angiogenesis and apoptosis. JACC 2006; 48: A56A66.

Google Scholar

Cotter G, Deniau B, Davison B, et al. Optimization of evidence-based heart failure medications after an acute heart failure admission: a secondary analysis of the STRONG-HF randomized clinical trial. JAMA Cardiol 2024; 9: 114-24.

Google Scholar

Okuyama H, Langsjoen PH, Hamazaki T, et al. Statins stimulate atherosclerosis and heart failure: pharmacological mechanisms. Exp Rev Clin Pharmacol 2015; 8: 189-99.

Google Scholar

Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007; 357: 2248-61.

Google Scholar

Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 1231-9.

Google Scholar

Preiss D, Campbell RT, Murray HM, et al. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J 2015; 36: 1536-46.

Google Scholar

10.

Oikonomou E, Siasos G, Zaromitidou M, et al. Atorvastatin treatment improves endothelial function through endothelial progenitor cells mobilization in ischemic heart failure patients. Atherosclerosis 2015; 238: 159-64.

Google Scholar

11.

Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, et al. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018; 39: 331353.

Google Scholar

12.

Rogers JK, Jhund PS, Perez AC, et al. Effect of rosuvastatin on repeat heart failure hospitalizations: the CORONA Trial (Controlled Rosuvastatin Multinational Trial in Heart Failure). JACC Heart Fail 2014; 2: 289-97.

Google Scholar

13.

Cleland JG, McMurray JJ, Kjekshus J. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) J Am Coll Cardiol 2009; 54: 1850-9.

Google Scholar

14.

Bielecka-Dabrowa A, Banach M, Wittczak A, et al. The role of nutraceuticals in heart failure muscle wasting as a result of inflammatory activity. The International Lipid Expert Panel (ILEP) Position Paper. Arch Med Sci 2023; 19: 841-64.

Google Scholar

15.

Liu G, Zheng XX, Xu YL, Ru J, Hui RT, Huang XH. Meta-analysis of the effect of statins on mortality in patients with preserved ejection fraction. Am J Cardiol 2014; 113: 1198-204.

Google Scholar

16.

Banach M, Serban C, Ursoniu S, et al.; Lipid and Blood Pressure Meta-analysis Collaboration (LBPMC) Group. Statin therapy and plasma coenzyme Q10 concentrations: a systematic review and meta-analysis of placebo-controlled trials. Pharmacol Res 2015; 99: 329-36.

Google Scholar

17.

Fukuta H, Goto T, Wakami K, Ohte N. The effect of statins on mortality in heart failure with preserved ejection fraction: a meta-analysis of propensity score analyses. Int J Cardiol 2016; 214: 301-6.

Google Scholar

18.

Lipinski MJ, Cauthen CA, Biondi-Zoccai GG, et al. Meta-analysis of randomized controlled trials of statins versus placebo in patients with heart failure. Am J Cardiol 2009; 104: 1708-16.

Google Scholar

19.

Alehagen U, Benson L, Edner M2, Dahlström U, Lund LH. Association between use of statins and mortality in patients with heart failure and ejection fraction of ≥50. Inhibitors of 3hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase occasionally cause myopathy characterized by weakness, pain, and elevated serum creatine phosphokinase (CK). Circ Heart Fail 2015; 8: 862-70.

Google Scholar

20.

Ugovšek S, Zupan J, Rehberger Likozar A, Šebeštjen M. Influence of lipid-lowering drugs on inflammation: what is yet to be done? Arch Med Sci 2021; 18: 855-69.

Google Scholar

21.

Bytyçi I, Penson PE, Mikhailidis DP, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J 2022; 43: 3213-23.

Google Scholar

22.

Sarzani R, Spannella F, Di Pentima C, Giulietti F, Landolfo M, Allevi M. Molecular therapies in cardiovascular diseases: small interfering RNA in atherosclerosis, heart failure, and hypertension. Int J Mol Sci 2023; 25: 328.

Google Scholar

23.

Adamo M, Pagnesi M, Di Pasquale M, et al. Differential biomarker expression in heart failure patients with and without mitral regurgitation: insights from BIOSTAT-CHF. Int J Cardiol 2024; 399: 131664.

Google Scholar

24.

White HD, Schwartz GG, Szarek M, et al.; ODYSSEY OUTCOMES Investigators. Alirocumab after acute coronary syndrome in patients with a history of heart failure. Eur Heart J 2022; 43: 1554-65.

Google Scholar

25.

Chapa JJ, McCollum JC, Bisono JQ, Prakash RS, Guglin ME, Rao RA. PCSK9 inhibition in patients after heart transplantation: a retrospective review and literature analysis. Curr Heart Fail Rep 2023; 20: 168-78.

Google Scholar

26.

Takano H, Mizuma H, Kuwabara Y, et al.; PEARL Study Investigators. Effects of pitavastatin in Japanese patients with chronic heart failure: the Pitavastatin Heart Failure Study (PEARL Study). Circ J 2013; 77: 917-25.

Google Scholar

27.

Bielecka-Dabrowa A, Bytyçi I, Von Haehling S, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis 2019; 18: 188.

Google Scholar

28.

Katsiki N, Filippatos T, Vlachopoulos C, et al. Executive summary of the Hellenic Atherosclerosis Society guidelines for the diagnosis and treatment of dyslipidemias – 2023. Atheroscler Plus 2024; 55: 74-92.

Google Scholar

Submit your paper

eISSN:	1896-9151
ISSN:	1734-1922